Table 2 Tissue microarray immunohistochemistry results

From: Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer

 

BRCA1 Carrier (n=78)

Noncarrier (n=119)

P-value

EGFR—n (%)

  

0.10

 Negative

14 (18.9)

35 (29.7)

 

 Positive

60 (81.1)

83 (70.3)

 

 Unknowna

4

1

 

Cytokeratin 5/6—n (%)

  

0.002

 Negative

19 (24.4)

55 (46.2)

 

 Positive

59 (75.6)

64 (53.8)

 

 Unknowna

0

0

 

Cytokeratin 14—n (%)

  

0.42

 Negative

37 (48.7)

65 (54.6)

 

 Positive

39 (51.3)

54 (45.4)

 

 Unknowna

2

0

 

Androgen receptor—n (%)

  

0.02

 Negative

69 (90.8)

90 (76.3)

 

 Weakly positive

4 (5.3)

9 (7.6)

 

 Positive

3 (3.9)

19 (16.1)

 

 Unknowna

2

1

 

Androgen receptor—n (%)

  

0.01

 Negative

69 (90.8)

90 (76.3)

 

 Weakly positive/positive (⩾1%)

7 (9.2)

28 (23.7)

 

 Unknowna

2

1

 

Androgen receptor—n (%)

  

0.01

 Negative/weakly positive

73 (96.1)

99 (83.9)

 

 Positive (>10%)

3 (3.9)

19 (16.1)

 

 Unknowna

2

1

 

PD-L1 cancer—n (%)

  

0.35

 Negative

58 (77.3)

84 (71.2)

 

 Positive (⩾1%)

17 (22.7)

34 (28.8)

 

 Unknowna

3

1

 

PD-L1 cancer/inflammatory—n (%)

  

0.17

 Negativeb

3 (4.3)

11 (10.3)

 

 Positive (⩾ 1%)c

67 (95.7)

96 (89.7)

 

 Unknown

8

12

 
  1. aInsufficient measurable tumor.
  2. bCancer cells and inflammatory cells lack PD-L1 staining.
  3. cEither cancer cells or inflammatory cells stain for PD-L1.
Back to article page